Aktis Oncology filed for an initial public offering to finance clinical development of its miniprotein radioconjugates, the company disclosed in regulatory filings and media reports. The Boston‑based biotech, backed by Eli Lilly, Merck, Novartis and Bristol Myers Squibb, aims to fund phase 1b testing of Ac‑AKY‑1189 (Nectin‑4) and advance a pipeline of alpha‑emitting radiopharmaceuticals. Aktis emphasized partnerships and prior private capital—about $346 million raised—and flagged preliminary phase 1b readouts expected in coming years as a use of proceeds. The filings position Aktis as an early test of investor appetite for radiopharma names after a slow biotech IPO market in 2025.